BCR : Analysis & Opinions

  1. AngioDynamics (ANGO) Hits 52-Week High on Positive View - Analyst ...

    December 18, 2014
    Shares of AngioDynamics Inc (ANGO) reached a 52-week high of $19.20 on Dec 17, 2014.
  2. CR Bard Strong on Acquisitions, FDA Nod for Lutonix DCB - Analyst ...

    December 17, 2014
    CR Bard's initiative to introduce its products in the emerging markets is delivering accretive returns, as the company continues ...
  3. C. R. Bard Inc. (BCR): New Analyst Report from Zacks Equity Research ...

    December 16, 2014
    C. R
  4. MedTech Defies Sequestration, M&As Steal the Show - Industry ...

    August 26, 2014
    MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
  5. MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook

    May 1, 2014
    MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook
  6. MedTech Industry Stock Update - Jan 2014 - Industry Outlook

    January 7, 2014
    MedTech Industry Stock Update - Jan 2014 - Industry Outlook
  7. MedTech Industry Stock Update - Sept 2013 - Industry Outlook

    September 10, 2013
    MedTech Industry Stock Update - Sept 2013 - Industry Outlook
  8. It Gets A Little Harder From Here For Covidien

    April 29, 2013
    Expectations are the bigger issue for Covidien, as underlying growth is still pretty good on a relative basis.
  9. AngioDynamics Still Struggling To Get Back On Track

    April 10, 2013
    Ongoing revenue growth struggles and eroding market share is making the deep-value case harder at AngioDynamics.
  10. Synergy Starts SP-333 Phase I Study - Analyst Blog

    January 29, 2013
    Synergy Pharmaceuticals Inc. (SGYP) recently initiated a phase Ib study on its inflammatory bowel disease (IBD) candidate, ...
  11. Isis Pharma Updates on its Pipeline - Analyst Blog

    January 11, 2013
    Isis Pharmaceuticals, Inc. (ISIS) recently provided an update on its pipeline. Isis Pharma boasts of a robust pipeline. The ...
  12. ANGO Beats on EPS, Tweaks View - Analyst Blog

    January 4, 2013
    AngioDynamics Inc. (ANGO) reported adjusted earnings of 10 cents per share for the second quarter of fiscal 2013 ended November ...
  13. Endo Health Solutions Needs Some Solutions Of Its Own

    November 7, 2012
    Can Endo reestablish itself as a quality healthcare name?
  14. AngioDynamics Wins GPO Contract - Analyst Blog

    October 11, 2012
    Therapeutic and diagnostic devices maker AngioDynamics (ANGO) recently won a contract with HealthTrust Purchasing Group, ...
  15. Teleflex and Novation Team Up - Analyst Blog

    September 10, 2012
    Teleflex Incorporated (TFX), a global leader in medical devices used in critical care and surgery, was recently awarded an ...
  16. Slew of Product Recalls at Covidien - Analyst Blog

    August 24, 2012
    Recently, health care products major Covidien plc. (COV) has been hit by a number of product recalls, the most significant ...
  17. Becton Dickinson Safe And Steady

    June 13, 2012
    Becton stands out for having one of the clearest growth strategies in its field as well as a solid track record of delivering ...
  18. Covidien Promotes Zogenix's Product - Analyst Blog

    June 8, 2012
    The pharmaceutical unit of Covidien plc (COV) and Zogenix Inc. (ZGNX) have recently agreed to co-endorse a prescription medicine ...
  19. Covidien Reports, Ready To Spin Off Pharma

    May 4, 2012
    Covidien is looking to bridge its current valuation discount with a number of purer-play rivals.
  20. CareFusion: Is It Still Cheap?

    May 3, 2012
    The biggest concern investors have with CareFusion is its low return on invested capital. Until it creates higher free cash ...
  21. Modest But Predictable Growth At C.R. Bard

    April 26, 2012
    C.R. Bard is posting modest operational growth but there is ample downside protection.
  22. Find A Biotech Stock That's On A Winning Streak

    March 22, 2012
    Investors follow momentum trends because positive sentiment on a company can cause the momentum to persist.
  23. 2011 - Another Sick Year For Larger Med-Tech

    December 29, 2011
    Larger healthcare companies are still getting sickly returns in the market.
  24. Covidien Delivers Once Again

    November 21, 2011
    Covidien is overlooked and undervalued.
  25. Is Hologic A Coiled Spring?

    November 11, 2011
    Hologic looks cheap on even modest growth recovery expectations.
  26. If CareFusion Can Execute, This Is A Major Bargain

    November 9, 2011
    CareFusion has to make some improvements, but it could really reward investors.
  27. Endo And Forest – Dumpster-Diving In Pharma

    September 21, 2011
    Endo and Forest have problems; however, the valuations seem excessively low.
  28. BD Healthy, But No Great Bargain

    August 9, 2011
    BD is not the cheapest health care name, but it comes with a lot of quality.
  29. Covidien's Image Starting To Change

    August 3, 2011
    Find out why Covidien is much better than many investors assume.
  30. Heavily Shorted Stocks Near Their Highs

    March 21, 2011
    When hot stocks have high short interest, investors should pause and reexamine their thesis.
  31. 6 Stocks At 52-Week Lows

    January 31, 2011
    Are these companies on a downward spiral or gearing up for a rebound?
  32. Money To Be Made In Medical Devices

    September 22, 2010
    New advances in medical devices will not only help patients live better lives, but they'll power portfolios as well.
  33. Covidien Happy With Tyco Split

    March 3, 2010
    Projections for double-digit profit increases at Covidien would easily take care of any valuation concerns at current levels. ...
  34. Four High-Flying Pharmaceutical Companies

    October 28, 2009
    A look at some of the best-performing stocks year to date - up anywhere from 400% to 2000%.
  35. Mid Cap Stocks That Have Been Left Behind

    May 15, 2009
    Despite the huge market rally over the last two months, there are several mid cap stocks that have not participated. Investors ...
  36. Mileage Matters More Than Muscle

    March 26, 2008
    Sometimes consistency produces better returns than undependable potential. Medical equipment company C.R. Bard is proof. ...
Trading Center